Cellectar Biosciences, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2014. Cellectar is a clinical-stage biopharmaceutical company developing cancer imaging and treatment candidates. It reported no product revenue; its operations and reported losses primarily reflect research and development and corporate costs.
Financial performance
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Research and development | $1.47 million | $2.07 million | $4.57 million | $5.31 million |
| General and administrative | $803,000 | $844,000 | $2.85 million | $3.04 million |
| Restructuring costs | None | None | $222,000 | None |
| Operating loss | $2.27 million | $2.91 million | $7.64 million | $8.35 million |
| Net loss | $506,000 | $1.32 million | $5.53 million | $6.83 million |
| Basic and diluted loss per share | $0.10 | $0.46 | $1.54 | $2.47 |
There was no revenue, so revenue margins are not applicable. Q3 and nine-month net losses were reduced by noncash gains from revaluing derivative warrants: $2.02 million and $2.54 million, respectively. The nine-month 2014 loss also included $436,000 of net interest expense, including noncash discount accretion on convertible debt.
Cash, debt and liquidity
- Cash and cash equivalents were $11.58 million at September 30, 2014, versus $2.42 million at December 31, 2013. Restricted cash was $55,000.
- Cash used in operations was $6.70 million for the first nine months, compared with $6.48 million in 2013. Investing activities used $17,000; financing activities provided $15.87 million.
- Current assets were $11.92 million and current liabilities $2.07 million. Total liabilities were $2.57 million. Notes payable totaled $450,000, of which $103,325 was current; the remaining balance was a Wisconsin Department of Commerce loan.
- The company raised $13.48 million gross in an August public offering of common stock and warrants, receiving $11.88 million net. It exchanged $4.0 million principal and approximately $172,000 accrued interest on convertible debentures for 1,109,690 shares and warrants.
- Management said cash on hand was expected to fund operations through the third quarter of 2015. Further operations depend on raising additional capital; the filing provides no assurance of financing on acceptable terms.
Changes and notable items
- Nine-month R&D expense fell 14% year over year, mainly due to restructuring-related compensation savings and lower purchased services and capital-related costs. G&A declined 6%, largely from lower compensation and directors’ fees, partly offset by higher legal fees.
- The company completed a 1-for-20 reverse stock split in June 2014 and listed its common stock and offering warrants on Nasdaq. Shares outstanding were 7,562,762 as of November 10, 2014, compared with 2,869,739 at year-end 2013.
- At September 30, 6,604,096 warrants and 619,166 stock options were outstanding. The August offering warrants generally have a $4.68 exercise price and expire in 2019; potential exercise would be dilutive.
- Derivative warrant liabilities declined from $3.36 million at year-end 2013 to $820,000. The related fair-value gains are noncash and depend on valuation assumptions, including stock price, volatility and financing expectations.
- The company recorded $222,000 in restructuring costs during the nine months, including severance and office-closure costs, and said it did not anticipate further relocation-related costs.
Pipeline, outlook and risks
- I-124-CLR1404: Phase 1/2 imaging studies were ongoing; a Phase 2 glioblastoma trial begun in March 2014 was expected to complete in the first half of 2015. FDA orphan designation for glioma was granted in April 2014.
- I-131-CLR1404: FDA clearance for an IND in multiple myeloma was received in September 2014; orphan drug designation was requested. The company had completed enrollment in a Phase 1b study of advanced solid tumors in November 2013.
- CLR1502 remained preclinical. The company anticipated filing an IND in Q4 2014 or Q1 2015.
- Management expected operating losses to continue for the foreseeable future. The filing highlights financing needs, clinical and regulatory uncertainty, possible delays or failure of product candidates, competition, and the risk that insufficient funding could force programs to be delayed, reduced or discontinued.
- The Massachusetts Appeals Court affirmed the company’s favorable judgment in the ZAO BAM dispute on November 10, 2014. The company did not expect the matter to materially affect its financial position, results or cash flows.
- Management reported that disclosure controls were effective as of September 30, 2014 and that no material change in internal control over financial reporting occurred during the quarter.
Key facts for investors to verify
- Whether the reported cash runway through Q3 2015 remains sufficient given actual clinical spending and future financing needs.
- Progress and timing of the glioblastoma imaging trial, the multiple myeloma program and the anticipated CLR1502 IND filing.
- Potential dilution from the large outstanding warrant and option balances, and the terms and exercise conditions of those securities.
- The cash-burn trend and the extent to which reported net losses reflect noncash derivative revaluation gains and debt-related interest charges.
- Whether additional capital can be raised on acceptable terms before existing resources are depleted.